DNQX is a competitive, non-NMDA glutamate receptor antagonist (IC50s = 0.5 and 0.1 μM for AMPA and kainate receptors, respectively versus IC50 = 40 μM for NMDA receptors). This compound has been used to specifically target AMPA and kainate receptor responses and thus differentiate from that of NMDA receptors. DNQX does not stimulate a robust long-term potentiation in the hippocampus.
